300 Technology Square
Tolerx, Inc. is a biopharmaceutical company engaged in discovering and developing new therapies designed to treat patients with immune related diseases - such as type 1 diabetes, psoriasis, and others - by reprogramming the immune system following a short course of therapy. Tolerx is developing its CD3 monoclonal antibody, otelixizumab, in collaboration with GlaxoSmithKline and the Juvenile Diabetes Research Foundation. Tolerx is developing with Genentech, a CD4 monoclonal antibody, MTRX1011. Tolerx is also engaged in the preclinical development of other antibodies that may shift or modulate the immune system.
For more information about Tolerx, please visit the company’s website at www.tolerx.com.